No Data
Shandong Sinobioway Biomedicine (002581.SZ): plans to sign a "Sales Contract" with Jiangsu Suhao.
On March 12, GLONGLY announced that Shandong Sinobioway Biomedicine (002581.SZ) announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. (referred to as "Shandong Yandu") signed a "Sales Contract" with Jiangsu Suhao Innovation Technology Group Co., Ltd. (referred to as "Jiangsu Suhao") to procure the required supply liquid system, chromatographic system, fillers, and reaction bags for the production workshop of recombinant neurotrophic factor eye drops for the ShanDong Sinobioway Biomedical Industrial Park project.
Companies Like Shandong Sinobioway Biomedicine (SZSE:002581) Are In A Position To Invest In Growth
Unnamed Pharmaceuticals: 2024 Annual Results Forecast
Sinobioway Biomedicine's Unit Signs 65 Million Yuan Construction Deal for Industrial Park
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 27% Share Price Plunge Could Signal Some Risk
Shandong Sinobioway Biomedicine (002581.SZ): plans to increase the capital of its wholly-owned subsidiary ShanDong YanDu by 0.29 billion yuan.
On January 3, Gelonghui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced the company is using its own funds to increase capital by 0.29 billion yuan for its wholly-owned subsidiary ShanDong Yandu Biotechnology Co., Ltd. (referred to as "ShanDong Yandu"), of which 0.29 billion yuan will be included in registered capital and 0 yuan in capital surplus. After the capital increase, ShanDong Yandu's registered capital will reach 0.3 billion yuan, remaining a wholly-owned subsidiary of the company. Meanwhile, the Board of Directors has authorized the company's management to handle the specific procedures related to the capital increase.
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
